Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Prospective Epidemiological Study Evaluating Occurrences of Influenza-like Illness
- Conditions
- Influenza
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Osivax
- Target Recruit Count
- 119
- Registration Number
- NCT06779981
- Locations
- 🇧🇪
Centre for Vaccinology (CEVAC), Ghent, Belgium
Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836
- Conditions
- Vaccine-Preventable DiseasesInfluenza
- Interventions
- Biological: OVX836 shot
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Osivax
- Target Recruit Count
- 117
- Registration Number
- NCT06582277
- Locations
- 🇧🇪
Centre for Vaccinology (CEVAC) Ghent University Hospital, Ghent, Belgium
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Osivax
- Target Recruit Count
- 48
- Registration Number
- NCT06128382
- Locations
- 🇫🇷
CIC Cochin Pasteur CIC 1417 Hôpital Cochin, Paris, France
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
- Conditions
- Influenza
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Osivax
- Target Recruit Count
- 478
- Registration Number
- NCT05734040
- Locations
- 🇦🇺
Paratus Clinical Research Central Coast, Kanwal, New South Wales, Australia
🇦🇺Emeritus Research Sydney, Sydney, New South Wales, Australia
🇦🇺Paratus Clinical Research Western Sydney, Sydney, New South Wales, Australia
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
- Conditions
- Influenza
- Interventions
- Biological: OVX836 480µgBiological: Saline Solution
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Osivax
- Target Recruit Count
- 2850
- Registration Number
- NCT05569239
- Prev
- 1
- 2
- Next
News
Osivax Secures $19.5M BARDA Award to Advance Universal Influenza Vaccine OVX836
Osivax received $19.5 million in funding from BARDA to accelerate development of OVX836, a next-generation broad-spectrum influenza A vaccine candidate.
Osivax Completes Phase 2a Booster Trial for Broad-Spectrum Influenza Vaccine OVX836
Osivax announced completion of patient visits in its Phase 2a booster trial evaluating OVX836, a broad-spectrum influenza A vaccine candidate targeting the highly conserved nucleoprotein antigen.
Osivax Raises €10M in Series B Funding to Advance Broad-Spectrum Influenza Vaccine Development
Osivax secures €10 million in Series B financing, with strategic investment from Japanese pharmaceutical leader Meiji Seika Pharma, to accelerate development of broad-spectrum influenza vaccine candidates.
Osivax Initiates Phase 2a Booster Trial of Broad-Spectrum Influenza Vaccine OVX836
Osivax has dosed the first participant in a Phase 2a clinical trial evaluating OVX836 as a booster for its broad-spectrum influenza vaccine candidate.